CMSC

TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 1, 2023
CMS, SG, Centers for Medicare & Medicaid Services, Conference call, CD20, Clinical trial, Prescription, Finance, Multiple sclerosis, TG, CMSC, Sale, II, Medicare, RMS, Acquisition, Patient, Physician, R, FDA, EC, Therapy, Conference, Food, European Commission, D, Video game, Pharmaceutical industry, Health insurance, Clothing, Cryptocurrency

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We are pleased to report our second quarter 2023 results, representing our first full quarter of BRIUMVI sales, which exceeded our expectations.

Key Points: 
  • Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We are pleased to report our second quarter 2023 results, representing our first full quarter of BRIUMVI sales, which exceeded our expectations.
  • Achieved $16 million in BRIUMVI net sales for the second quarter 2023, total net product revenue of $23.8 million since launch.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $144.9 million as of June 30, 2023.
  • The Company will host a conference call today, August 1, 2023, at 8:30 AM ET, to discuss the Company’s financial results from the second quarter, ended June 30, 2023, the Neuraxpharm ex-U.S. commercialization agreement, and provide a business outlook for the remainder of 2023.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
Friday, June 2, 2023
Publication, Multiple sclerosis, TG, CMSC, II, RMS, Public, Patient, Therapy, Pharmaceutical industry, Fatigue

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

Key Points: 
  • NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.
  • A link to the oral presentation is included below.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We were excited to present additional analyses from the ULTIMATE I & II Phase 3 trails last night at the CMSC annual meeting.
  • We believe the data continue to support the unique attributes of BRIUMVI and we look forward to continuing to present additional data at medical meetings throughout the year.”
    Oral Presentation: Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II
    The data presentation is also available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.

Octave Presents New Data at CMSC Annual Meeting 2023, Adding to Growing Evidence Supporting All Dimensions of its Comprehensive Precision Care Solution for Multiple Sclerosis

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Health, Neurology, Biometrics, Other Health, Radiology, Pharmaceutical, Research, Managed Care, Infectious Diseases, General Health, Genetics, Health Technology, Science, Single, DMT, Silent, MSN, Hospital, UTI, Urinary tract infection, University of Michigan Institute for Social Research, Medicine, Robustness, Emergent, Multiple sclerosis, BSN, CMSC, MS, Nursing, DMTS, DSM-IV codes, MRI, DO, PHN, Acquisition, MD, Patient, Physician, Neuroradiology, Center of excellence, Annual general meeting, Biology, RN, Poster, Hanusch, Medical imaging, Pharmaceutical industry, Octave

The data adds to the growing evidence supporting all dimensions of the company’s comprehensive Precision Care Solution for MS.

Key Points: 
  • The data adds to the growing evidence supporting all dimensions of the company’s comprehensive Precision Care Solution for MS.
  • “The robustness of learned protein signatures across datasets is reassuring evidence for the clinical utility of this methodology,” Dr. Foley said.
  • Discrepancies in clinical impressions, treatment recommendations, and follow-up orders may significantly impact patient outcomes and cost of care.
  • The posters and oral presentation presented by Octave at this year’s CMSC Annual Meeting showcase the growing breadth of data supporting its Precision Care Solution.

EQS-News: Immunic to Participate in Scientific and Investor Conferences in June

Retrieved on: 
Thursday, June 1, 2023
Aurora, Cleveland Clinic, Biotechnology, Multiple sclerosis, CMSC, MD, Neurological Institute of New York, Research, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:

Key Points: 
  • NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:
    May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunic’s management and business development teams will attend this conference in Boston and participate in partnering activities.
  • To schedule a meeting, please use the BIO International Convention partnering portal .

TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Aurora, Publication, Multiple sclerosis, TG, CMSC, II, RMS, Patient, Canadian International Council, Therapy, Pharmaceutical industry, Fatigue

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), to be presented at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 31 - June 4, 2023, in Aurora, Colorado.

Key Points: 
  • NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), to be presented at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 31 - June 4, 2023, in Aurora, Colorado.
  • The abstract is now available online and can be accessed on the International Journal of MS Care (IJMSC) website at www.ijmsc.org , or by following this direct link: https://doi.org/10.7224/1537-2073-25.s1.1 .
  • Details of the presentation are included below.
  • Oral Presentation: Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II
    Following the presentation, the data will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

Retrieved on: 
Wednesday, May 31, 2023
Railway Workers' Union (Austria), Macrophage, Barts and The London School of Medicine and Dentistry, Week, Disability, Research, Multiple sclerosis, CMSC, Queen Mary University of London, MS, St. Bartholomew's, Patient, Sanofi, Dentistry, Pivotal, CD40L, B cell, Blizard Building, Pharmaceutical industry, Vaccine, Neurology

Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placebo

Key Points: 
  • Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placebo
    Paris, May 31 2023.
  • New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis (MS).
  • Following 12 weeks of therapy, the number of new gadolinium-enhancing (GdE) T1-lesions was reduced by 89% and 79% in the higher- and lower-dose treatment arms, respectively, compared with placebo, meeting the study’s primary endpoint.
  • A substantial unmet need remains in MS for highly effective and well-tolerated treatment options that provide sustainable control of disease activity and disability progression, while minimizing risks.

Immunic to Participate in Scientific and Investor Conferences in June

Retrieved on: 
Tuesday, May 30, 2023
Aurora, Cleveland Clinic, Biotechnology, Multiple sclerosis, CMSC, MD, Neurological Institute of New York, Research, Vaccine, Short course immune induction therapy

NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:

Key Points: 
  • NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:
    May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunic's management and business development teams will attend this conference in Boston and participate in partnering activities.
  • To schedule a meeting, please use the BIO International Convention partnering portal .

Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

Retrieved on: 
Wednesday, May 24, 2023
Aurora, Exercise, Education, Result, Pons, HSDT, Quality of life, Hope, Research, Brain, Multiple sclerosis, CMSC, MS, Nerve, Annual general meeting, Intellectual disability, Multiple Sclerosis International Federation, Tongue, Convention center, Pharmaceutical industry, Helios

The CMSC conference brings together renowned experts, healthcare professionals and industry leaders to exchange knowledge, explore advancements in multiple sclerosis (MS) research and discuss the latest therapeutic approaches.

Key Points: 
  • The CMSC conference brings together renowned experts, healthcare professionals and industry leaders to exchange knowledge, explore advancements in multiple sclerosis (MS) research and discuss the latest therapeutic approaches.
  • Sharing this commitment to enhance the quality of life for people with MS, Helius is proud to participate in the meeting for the second year in a row.
  • MS is a complex neurological condition affecting millions worldwide, causing varying degrees of physical and cognitive disabilities.
  • As a leader in the healthcare industry, Helius is dedicated to developing innovative solutions to address the challenges faced by individuals with MS experiencing mobility issues.

NeurologyLive® and CMSC Announce Giants of Multiple Sclerosis® 2023 Class of Inductees

Retrieved on: 
Wednesday, April 26, 2023
Aurora, Sclerosis, Steering Committee for Humanitarian Response, Cleveland Clinic, Mayo Clinic, FRCP, MSN, Emeritus, Schapiro, Giant, Nursing, Bristol Myers Squibb, Multiple sclerosis, APRN, CMSC, Multiple, Committee, Patient, Annual general meeting, BHI, Merck Serono, Health, International Organization (journal), FAAN, Convention center, University of Virginia, Frankincense, Management, MD, Research

CRANBURY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- NeurologyLive ® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2023 Giants of Multiple Sclerosis® inductees.

Key Points: 
  • CRANBURY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- NeurologyLive ® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2023 Giants of Multiple Sclerosis® inductees.
  • Giants of Multiple Sclerosis is a premier neuroscience award that celebrates pioneers, innovators and difference makers who have been selected by their peers for their remarkable achievements in multiple sclerosis.
  • Launched in 2021, individuals named to the Giants of Multiple Sclerosis recognition program have made significant contributions to the field of multiple sclerosis.
  • Out of more than 200 nominations, only 10 individuals were selected to join the prestigious class of 2023 inductees.

Turtle & Hughes Names Michael Vitiello Vice President and National Sales Manager for Electrical Distribution Division

Retrieved on: 
Wednesday, January 18, 2023
Business operations, CMSC, Human resources, Culture, Mechanical, Baruch College, LDP, Torrent Power, Marketing, Vitiello, Engineering, ESG, Stevens Institute of Technology, Management, Turtle

LINDEN, N.J., Jan. 18, 2023 /PRNewswire-PRWeb/ -- Michael Vitiello, a 13-year veteran of Eaton Corp. has joined Turtle & Hughes as Vice President, National Sales Manager of its Electrical Distribution division. In his new role, he is responsible for the entirety of the company's Distribution Sales Leaders across the country. Vitiello will work to advance Turtle's technical solutions with national partners and its commitment to ESG leadership.

Key Points: 
  • LINDEN, N.J., Jan. 18, 2023 /PRNewswire-PRWeb/ -- Michael Vitiello, a 13-year veteran of Eaton Corp. has joined Turtle & Hughes as Vice President, National Sales Manager of its Electrical Distribution division.
  • In his new role, he is responsible for the entirety of the company's Distribution Sales Leaders across the country.
  • Vitiello will work to advance Turtle's technical solutions with national partners and its commitment to ESG leadership.
  • His earlier technical positions at Eaton included Hartford (CT) CMSC Engineering Manager, NYC Construction Lead Sales Engineer, NYC Residential/Light Commercial Sales Engineer, and LDP Technical Sales.